Tvardi Therapeutics financials
$1.28−3.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$6.6M | -$7.1M | -$7.6M | -$5.9M | -$8.9M |
| Net income | -$6.5M | -$6.8M | -$7.3M | -$5.5M | $4.2M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.69 | $-0.73 | $-0.68 | $-0.59 | $-1.00 |
| EBITDA | -$6.6M | -$7.0M | -$7.6M | -$5.9M | -$8.8M |
| Operating cash flow | -$9.2M | -$5.9M | -$5.7M | -$4.3M | -$5.9M |
| Free cash flow | -$9.2M | -$5.9M | -$5.7M | -$4.3M | -$5.9M |
| Diluted shares | 9.4M | 9.4M | 10.7M | 9.4M | 8.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $15.8M | $19.9M | $20.7M | $21.4M | $20.6M |
| Short-term investments | $0.00 | $5.1M | $10.1M | $15.0M | $20.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $17.5M | $25.8M | $32.1M | $39.0M | $43.8M |
| Total liabilities | $9.1M | $11.3M | $11.1M | $11.2M | $10.8M |
| Shareholders' equity | $8.4M | $14.5M | $20.9M | $27.9M | $32.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology